Linxuan Huang

Dongguan Key Laboratory Of Precision Diagnosis And Treatment For Tumors
Dongguan, 523059, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Safety, efficacy, pharmacokinetics, and mechanisms of novel 10B-boronophenylalanine combined with a radio-frequency quadrupole accelerator in boron neutron capture therapy: A preclinical study in head and neck squamous cell carcinoma.

Safety, efficacy, pharmacokinetics, and mechanisms of novel 10B-boronophenylalanine combined with a radio-frequency quadrupole accelerator in boron neutron capture therapy: A preclinical study in head and neck squamous cell carcinoma.

Journal: Precision radiation oncology

Published: January 29, 2026

Small-Molecule Boron-10-Enriched Carriers with Exceptional Aqueous Solubility for Enhanced Boron Neutron Capture Therapy of Malignant Tumors.

Small-Molecule Boron-10-Enriched Carriers with Exceptional Aqueous Solubility for Enhanced Boron Neutron Capture Therapy of Malignant Tumors.

Journal: Research (Washington, D.C.)

Published: December 16, 2025

LDRT combined with anti-PD-1 promotes tumor regression in head and neck squamous cell carcinoma through tumor metaprogram evolution and immune cell reprogramming.

LDRT combined with anti-PD-1 promotes tumor regression in head and neck squamous cell carcinoma through tumor metaprogram evolution and immune cell reprogramming.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 17, 2025

Hydroxy-Safflower Yellow A Inhibits Breast Cancer Growth via Tumor-Associated Macrophages/CCL5/Tissue Resident Memory T Cell Signaling.

Hydroxy-Safflower Yellow A Inhibits Breast Cancer Growth via Tumor-Associated Macrophages/CCL5/Tissue Resident Memory T Cell Signaling.

Journal: BioFactors (Oxford, England)

Published: September 17, 2025

Lactylation-related gene signatures for prognosis and treatment response prediction in radiation-resistant non-small cell lung cancer.

Lactylation-related gene signatures for prognosis and treatment response prediction in radiation-resistant non-small cell lung cancer.

Journal: Discover oncology

Published: May 29, 2025

Correction: Long non-coding RNA MIR4435-2HG modulates pancreatic cancer stem cells and chemosensitivity to gemcitabine by targeting the miR-1252-5p/STAT1.

Correction: Long non-coding RNA MIR4435-2HG modulates pancreatic cancer stem cells and chemosensitivity to gemcitabine by targeting the miR-1252-5p/STAT1.

Journal: Journal of translational medicine

Published: May 09, 2025

Joint Exposure to Multiple Air Pollutants, Genetic Susceptibility, and Risk of Heart Failure in Cancer Patients: A Prospective Study in UK Biobank.

Joint Exposure to Multiple Air Pollutants, Genetic Susceptibility, and Risk of Heart Failure in Cancer Patients: A Prospective Study in UK Biobank.

Journal: Clinical cardiology

Published: May 07, 2025

J-type assembled Pt(IV)-coordinated carbon dots for near-infrared light-triggered pyroptosis.

J-type assembled Pt(IV)-coordinated carbon dots for near-infrared light-triggered pyroptosis.

Journal: Light, science & applications

Published: December 10, 2024

Long non-coding RNA MIR4435-2HG modulates pancreatic cancer stem cells and chemosensitivity to gemcitabine by targeting the miR-1252-5p/STAT1.

Long non-coding RNA MIR4435-2HG modulates pancreatic cancer stem cells and chemosensitivity to gemcitabine by targeting the miR-1252-5p/STAT1.

Journal: Journal of translational medicine

Published: November 27, 2024

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.

Journal: Nature communications

Published: October 15, 2024

MAL, a potential immunotherapy target, is associated with poor prognosis in cancer patients.

MAL, a potential immunotherapy target, is associated with poor prognosis in cancer patients.

Journal: Cellular and molecular biology (Noisy-le-Grand, France)

Published: March 04, 2024

Identification of ALG3 as a potential prognostic biomarker in lung adenocarcinoma.

Identification of ALG3 as a potential prognostic biomarker in lung adenocarcinoma.

Journal: Heliyon

Published: February 23, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026